scholarly journals Measuring Duchenne muscular dystrophy impact: development of a proxy-reported measure derived from PROMIS item banks

2021 ◽  
Vol 16 (1) ◽  
Author(s):  
Carolyn E. Schwartz ◽  
Roland B. Stark ◽  
David Cella ◽  
Katrina Borowiec ◽  
Katherine L. Gooch ◽  
...  

Abstract Background Person-reported outcomes measurement development for rare diseases has lagged behind that of more common diseases. In studies of caregivers of patients with rare diseases, one relies on proxy report to characterize this disability. It is important to measure the child’s disability accurately and comprehensively because it affects caregiver burden. We aimed to create a condition-specific caregiver proxy-report measure for Duchenne Muscular Dystrophy (DMD) in order to understand the impact of DMD on the caregiver. Drawing on relevant item banks from the Patient-Reported Outcome Measurement Information System (PROMIS), we sought to confirm their reliability and validity in the target sample of DMD caregivers. Methods This web-based study recruited DMD caregivers via Rare Patient Voice, patient-advocacy groups, and word of mouth. Recruitment was stratified by age of the caregiver’s child with DMD, which broadly represents stages of DMD progression: 2–7, 8–12, 13–17, and > 18. Telephone interviews with DMD parent-caregivers pretested possible measures for content validity. The web-based study utilized an algorithm to categorize respondents’ ambulatory status for tailored administration of PROMIS Parent-Proxy items as well as some new items developed based on caregiver interviews. Item response theory analyses were implemented. Results The study sample included 521 DMD caregivers representing equally the four age strata. The proxy-report measure included the following domains: fatigue impact, strength impact, cognitive function, upper extremity function, positive affect, negative affect, sleep-device symptoms, and mobility. The first five domains had strong psychometric characteristics (unidimensionality; acceptable model fit; strong standardized factor loadings; high marginal reliability). Negative Affect, covering anger, anxiety, depressive symptoms, and psychological stress, fit a bifactor model with good model fit, high marginal reliability, and strong factor loadings. The Sleep-device symptoms domain was not unidimensional, and the mobility domain did not have a simple structure due to residual correlations among items at opposite end of the mobility-disability continuum. These two domain scores were retained as clinimetric indices (i.e., uncalibrated scales), to achieve the overall goal of having a content-valid DMD-specific measure across all stages of disease severity. Conclusions The present study derived a DMD-specific proxy-report measure from PROMIS item banks and supplemental items that could potentially be utilized in caregiver research across all stages of the care recipient’s DMD. Future research will focus on assessing the responsiveness and validity of the measure over time and its comparison to DMD patient self-report.

2012 ◽  
Vol 153 (30) ◽  
pp. 1185-1190 ◽  
Author(s):  
Anett Földvári ◽  
Ildikó Szy ◽  
János Sándor ◽  
Gábor Pogány ◽  
György Kosztolányi

The long diagnostic delay is a characteristic problem of rare disease patients. Aims: Diagnostic delay was studied in 14 countries by EurordisCare2 involving patient organizations. Methods: 252 Hungarian patients (cystic fibrosis; Duchenne muscular dystrophy; tuberous sclerosis, retinitis pigmentosa, and Williams’ syndrome) completed the questionnaires. Results: The median delay was longer in Hungary than in Europe (cystic fibrosis: 227 vs. 45 days; Duchenne muscular dystrophy: 467 vs. 360 days; tuberous sclerosis: 155 vs. 120 days). Patients’ experience was similar in Hungary and in Europe. The proportion of misdiagnosis was 30.8% in Hungary (Europe: 41%), 34.8% of patients got diagnosis outside of living place region (EU: 26%) and 19.9% of them found the personal expenses too high (EU: 10%). Delivery of the diagnosis was unnecessary according to 27.4% of Hungarian patients (EU: 35%). Conclusions: The qualitative survey demonstrated that the problems with the diagnosis of rare diseases are widespread, the identified areas require interventions, and it confirmed the importance of centralized care. Orv. Hetil., 2012, 153, 1185–1190.


2015 ◽  
Vol 10 (01) ◽  
pp. 79
Author(s):  
Olivia Schreiber-Katz ◽  

Rare diseases represent a special challenge for the translation of new therapies into patient care. Duchenne muscular dystrophy (DMD) is a rare childhood-onset muscular dystrophy; curative treatment is not yet available. However, new therapies are emerging to fight this devastating disease. In order to establish an infrastructure to improve data harmonisation, knowledge on the disease, public awareness, industrial interest and trial readiness, patient registries are an indispensable resource. This article provides a short overview on their importance and benefits towards improving diagnosis and care.


Neurology ◽  
2021 ◽  
pp. 10.1212/WNL.0000000000011896
Author(s):  
Philip A. Powell ◽  
Jill Carlton ◽  
Donna Rowen ◽  
Fleur Chandler ◽  
Michela Guglieri ◽  
...  

ObjectiveBased on concerns over existing patient reported outcome measures (PROMs) for assessing quality of life (QoL) in Duchenne muscular dystrophy (DMD), we describe the mixed methods development of a new QoL PROM for use in boys and men with DMD: the DMD-QoL.MethodsThe DMD-QoL was developed in 3 stages. First, draft items were generated from 18 semi-structured qualitative interviews with boys and men with DMD, analysed using framework analysis. Second, cognitive debriefing interviews with patients (n = 10), clinicians (n = 8), and patients' parents (n = 10) were undertaken and a reduced item set selected and refined. Third, psychometric data on the draft items from a cross-sectional online survey (n = 102), and stakeholder input from patients and patients' parents, was used to produce the final questionnaire. Patient and public involvement and engagement was embedded throughout the process.ResultsFrom an initial draft of 47 items, a revised set of 27 items was produced at stage 2, and this set was further refined at stage 3 to generate the DMD-QoL, a 14-item QoL PROM. The DMD-QoL is designed for use from 7 years of age by proxy report and from 10 years of age by self or proxy report. The final measure showed good psychometric properties.ConclusionsThe DMD-QoL is a new 14-item QoL PROM for boys and men with DMD, with demonstrable content and face validity.


Sign in / Sign up

Export Citation Format

Share Document